COVID-19 in Congenital Heart Disease Study (COACHeD study) [COVID-19]

  • Research type

    Research Study

  • Full title

    COVID-19 in Congenital Heart Disease Study (COACHeD study)



  • Contact name

    Piers Daubeney

  • Contact email

  • Sponsor organisation

    Royal Brompton & Harefield NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 2 months, 16 days

  • Research summary

    \nThe coronavirus disease 2019 (COVID-19, SARS-CoV-2) pandemic has impacted all areas of global healthcare with significant changes to health infrastructure made to tackle the disease and manage the unprecedented case load. Severity of disease has been shown to be linked with age and those patients in ‘at risk’ groups including those with cardiovascular disease. More in depth studies are ongoing including Capacity COVID funded by the BHF and international severe acute respiratory and emerging infection consortium (ISARIC) COVID-19 database. In addition, the new condition ‘Paediatric multisystem inflammatory syndrome temporarily associated with COVID-19 “PIMS”’ has led to admissions in previously well children with documented myocardial and coronary artery involvement. \n\nCurrently there are no UK studies which assess the impact of COVID-19 on children and adults with congenital heart disease and children with acquired heart disease, therefore, in collaboration with the British Congenital Cardiac association we are conducting a UK wide surveillance study to assess the clinical impact of COVID-19 on these groups of patients. Participants will be identified through their local cardiac centre and their clinical notes will be reviewed to complete a standardised questionnaire on demographic data, their past medical and cardiac history and the impact that COVID-19 has had on their health. There will be no change or intervention to the participants’ clinical care. Patients will be contacted for informed consent by the local team using a standardised form. The results of this study will be published in a peer reviewed journal and presented at clinical meetings related to childhood and congenital heart disease. \n

  • REC name


  • REC reference


Shape the future of the HRA website.